


The Challenge

To apply IPA's B cell Select® technology on immunized rabbits to produce target-specific antibodies with a diverse repertoire of sequences.

Producing target-specific antibodies with a diverse repertoire




Results

88 positive hits were obtained from the initial B cell screening	56 produced an antigen-positive antibody (after cloning)	50 unique, combined, variable regions	32 unique, combined germlines	41 unique heavy variable regions
				49 unique kappa variable regions
				29 unique heavy CDR3s
				38 unique kappa CDR3s
				40 unique combined CDR3s
				19 unique heavy germlines
				21 unique kappa germlines

B cell Select® Results

Sequence Diversity



Conclusion

IPA's B cell Select® platform produces highly target-specific antibodies, while generating a diverse repertoire of sequences from a number of unique germlines.

For more information contact: info@ipatherapeutics.com



UNITED STATES | CANADA | EUROPE
©2022 ImmunoPrecise Antibodies (IPA). All rights reserved.



ipatherapeutics.com